Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.40 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859574 | 0.87 | GCK (0.43) | MAP4K4GCKMAPK14TRPA1HSPB1 | |
| SCHEMBL8900878 | 0.80 | HTT (0.64) | HTTMAP4K4ACHEBCHEGRIN1 | |
| SCHEMBL29663483 | 0.80 | HTT (0.64) | HTTMAP4K4ACHEBCHEGRIN1 | |
| SCHEMBL5256361 | 0.80 | MAP4K4 (0.49) | HTTMAP4K4MAPK14TRPA1HSPB1 | |
| SCHEMBL4849482 | 0.76 | TRPA1 (0.44) | MAP4K4GCKMAPK14TRPA1HSPB1 | |
| SCHEMBL8900322 | 0.73 | HTT (0.58) | HTTACHEBCHEGRIN1GRIN2A | |
| SCHEMBL21186019 | 0.71 | AXL (0.63) | HTTMAP4K4HSPB1SCN4A | |
| SCHEMBL29224064 | 0.71 | HTT (0.50) | HTTMAP4K4ACHEBCHEGRIN1 | |
| SCHEMBL3720623 | 0.70 | HTT (0.54) | HTTMAP4K4ACHEBCHE | |
| SCHEMBL18646614 | 0.69 | HSPB1 (0.58) | HSPB1ARSCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456185-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | DUNN JAMES P | 2007-07-19 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238698-B2 | Substituted quinazoline compounds useful as p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1620408-A2 | QUINAZOLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092144-A2 | QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | ROCHE PALO ALTO LLC | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167471-A1 | Substituted quinazoline compounds useful as p38 kinase inhibitors | MAPK1, MAPK7, MAPK3 | HTT 4013/4885MAP4K4 38/4885GCK 651/4885 |
| US-20040209904-A1 | Substituted quinazoline compounds useful as P38 kinase inhibitors | MAPK1, MAPK4, MAPK7 | HTT 4558/4885MAP4K4 31/4885GCK 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.